Isabel Cardoso

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8364907/publications.pdf

Version: 2024-02-01

66 papers	3,029 citations	147801 31 h-index	161849 54 g-index
68 all docs	68 docs citations	68 times ranked	3197 citing authors

#	Article	IF	Citations
1	Choroid Plexus in Alzheimerâ€™s Diseaseâ€”The Current State of Knowledge. Biomedicines, 2022, 10, 224.	3.2	23
2	Cu²⁺-binding to S100B triggers polymerization of disulfide cross-linked tetramers with enhanced chaperone activity against amyloid-Î² aggregation. Chemical Communications, 2021, 57, 379-382.	4.1	6
3	Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimerâ€™s Disease. Marine Drugs, 2021, 19, 343.	4.6	8
4	Exploring the Physiological Role of Transthyretin in Glucose Metabolism in the Liver. International Journal of Molecular Sciences, 2021, 22, 6073.	4.1	2
5	Neuroprotection in early stages of Alzheimerâ€™s disease is promoted by transthyretin angiogenic properties. Alzheimer's Research and Therapy, 2021, 13, 143.	6.2	7
6	Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease. European Journal of Medicinal Chemistry, 2021, 226, 113847.	5.5	15
7	Dynamic interactions and Ca2+-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding. Nature Communications, 2021, 12, 6292.	12.8	10
8	Repurposing Benzbromarone for Familial Amyloid Polyneuropathy: A New Transthyretin Tetramer Stabilizer. International Journal of Molecular Sciences, 2020, 21, 7166.	4.1	15
9	The S100B Alarmin Is a Dual-Function Chaperone Suppressing Amyloid-Î² Oligomerization through Combined Zinc Chelation and Inhibition of Protein Aggregation. ACS Chemical Neuroscience, 2020, 11, 2753-2760.	3.5	16
10	An Assay for Screening Potential Drug Candidates for Alzheimer's Disease That Act as Chaperones of the Transthyretin and Amyloidâ€Î² Peptides Interaction. Chemistry - A European Journal, 2020, 26, 17462-17469.	3.3	4
11	Oral Treatment with Iododiflunisal Delays Hippocampal Amyloid-Î² Formation in a Transgenic Mouse Model of Alzheimerâ€™s Disease: A Longitudinal in vivo Molecular Imaging Study1. Journal of Alzheimer's Disease, 2020, 77, 99-112.	2.6	6
12	Undiscovered Roles for Transthyretin: From a Transporter Protein to a New Therapeutic Target for Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 2075.	4.1	42
13	Calorimetric Studies of Binary and Ternary Molecular Interactions between Transthyretin, AÎ² Peptides, and Small-Molecule Chaperones toward an Alternative Strategy for Alzheimerâ€™s Disease Drug Discovery. Journal of Medicinal Chemistry, 2020, 63, 3205-3214.	6.4	22
14	Collagen type IV in brain vessels of an AD mouse model: modulation by transthyretin?. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 138-139.	3.0	3
15	Radiochemical examination of transthyretin (TTR) brain penetration assisted by iododiflunisal, a TTR tetramer stabilizer and a new candidate drug for AD. Scientific Reports, 2019, 9, 13672.	3.3	13
16	The neuronal S100B protein is a calcium-tuned suppressor of amyloid-Î² aggregation. Science Advances, 2018, 4, eaaq1702.	10.3	49
17	Insights on the Interaction between Transthyretin and AÎ² in Solution. A Saturation Transfer Difference (STD) NMR Analysis of the Role of Iododiflunisal. Journal of Medicinal Chemistry, 2017, 60, 5749-5758.	6.4	24
18	Transthyretin stability is critical in assisting beta amyloid clearanceâ€“ Relevance of transthyretin stabilization in Alzheimer's disease. CNS Neuroscience and Therapeutics, 2017, 23, 605-619.	3.9	38

#	Article	IF	Citations
19	Transthyretin neuroprotection in Alzheimer's disease is dependent on proteolysis. Neurobiology of Aging, 2017, 59, 10-14.	3.1	46
20	Resveratrol Administration Increases Transthyretin Protein Levels, Ameliorating AD Features: The Importance of Transthyretin Tetrameric Stability. Molecular Medicine, 2016, 22, 597-607.	4.4	37
21	Transthyretin participates in beta-amyloid transport from the brain to the liver- involvement of the low-density lipoprotein receptor-related protein 1?. Scientific Reports, 2016, 6, 20164.	3.3	71
22	Dual ligand immunoliposomes for drug delivery to the brain. Colloids and Surfaces B: Biointerfaces, 2015, 134, 213-219.	5.0	52
23	Aberrant zinc binding to immature conformers of metal-free copperâ€“zinc superoxide dismutase triggers amorphous aggregation. Metallomics, 2015, 7, 333-346.	2.4	29
24	Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease. Journal of Controlled Release, 2015, 198, 80-90.	9.9	27
25	Structural Heterogeneity and Bioimaging of S100 Amyloid Assemblies. , 2014, , 197-212.		4
26	Targeting a rare amyloidotic disease through rationally designed polymer conjugates. Journal of Controlled Release, 2014, 178, 95-100.	9.9	9
27	Transthyretin Stabilization by Iododiflunisal Promotes Amyloid-Î² Peptide Clearance, Decreases its Deposition, and Ameliorates Cognitive Deficits in an Alzheimer's Disease Mouse Model. Journal of Alzheimer's Disease, 2014, 39, 357-370.	2.6	45
28	The effect of a fluorinated cholesterol derivative on the stability and physical properties of cationic DNA vectors. Soft Matter, 2013, 9, 401-409.	2.7	16
29	Calcium Ions Promote Superoxide Dismutase 1 (SOD1) Aggregation into Non-fibrillar Amyloid. Journal of Biological Chemistry, 2013, 288, 25219-25228.	3.4	52
30	Small Molecules Present in the Cerebrospinal Fluid Metabolome Influence Superoxide Dismutase 1 Aggregation. International Journal of Molecular Sciences, 2013, 14, 19128-19145.	4.1	4
31	Intrinsically Disordered and Aggregation Prone Regions Underlie Î²-Aggregation in S100 Proteins. PLoS ONE, 2013, 8, e76629.	2.5	22
32	Transthyretin Decrease in Plasma of MCI and AD Patients: Investigation of Mechanisms for Disease Modulation. Current Alzheimer Research, 2012, 9, 881-889.	1.4	48
33	S100A6 Amyloid Fibril Formation Is Calcium-modulated and Enhances Superoxide Dismutase-1 (SOD1) Aggregation. Journal of Biological Chemistry, 2012, 287, 42233-42242.	3.4	36
34	Transthyretin: roles in the nervous system beyond thyroxine and retinol transport. Expert Review of Endocrinology and Metabolism, 2012, 7, 181-189.	2.4	11
35	Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A-Beta Peptide - Relevance in Alzheimer's Disease. PLoS ONE, 2012, 7, e45368.	2.5	39
36	Transthyretin Aggregation and Toxicity. , 2012, , 407-432.		0

#	Article	IF	Citations
37	Testing the Therapeutic Potential of Doxycycline in a Drosophila melanogaster Model of Alzheimer Disease. Journal of Biological Chemistry, 2011, 286, 41647-41655.	3.4	63
38	Gender-Dependent Transthyretin Modulation of Brain Amyloid-Î² Levels: Evidence from a Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 429-439.	2.6	40
39	Controlling Amyloidâ€Î² Peptide(1â€“42) Oligomerization and Toxicity by Fluorinated Nanoparticles. ChemBioChem, 2010, 11, 1905-1913.	2.6	42
40	Randomization of Amyloidâ€Î²â€Peptide(1â€42) Conformation by Sulfonated and Sulfated Nanoparticles Reduces Aggregation and Cytotoxicity. Macromolecular Bioscience, 2010, 10, 1152-1163.	4.1	35
41	Human metallothioneins 2 and 3 differentially affect amyloidâ€beta binding by transthyretin. FEBS Journal, 2010, 277, 3427-3436.	4.7	25
42	Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine, 2010, 8, 74.	4.4	149
43	Binding of epigallocatechinâ€3â€gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 2009, 583, 3569-3576.	2.8	122
44	Design and biological activity of Î²-sheet breaker peptide conjugates. Biochemical and Biophysical Research Communications, 2009, 380, 397-401.	2.1	45
45	Transthyretin binding to Aâ€Beta peptide â€“ Impact on Aâ€Beta fibrillogenesis and toxicity. FEBS Letters, 2008, 582, 936-942.	2.8	125
46	Amyloidogenic properties of transthyretinâ€like protein (TLP) from Escherichia coli. FEBS Letters, 2008, 582, 2893-2898.	2.8	5
47	Extracellular Matrix Markers for Disease Progression and Follow-Up of Therapies in Familial Amyloid Polyneuropathy V30M TTR-Related. Disease Markers, 2008, 25, 37-47.	1.3	21
48	Transthyretin Protects against A-Beta Peptide Toxicity by Proteolytic Cleavage of the Peptide: A Mechanism Sensitive to the Kunitz Protease Inhibitor. PLoS ONE, 2008, 3, e2899.	2.5	95
49	Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochemical Journal, 2007, 408, 131-138.	3.7	30
50	Transthyretin and Alzheimer's disease: Where in the brain?. Neurobiology of Aging, 2007, 28, 713-718.	3.1	97
51	Impairment of the ubiquitinâ€“proteasome system associated with extracellular transthyretin aggregates in familial amyloidotic polyneuropathy. Journal of Pathology, 2007, 213, 200-209.	4.5	16
52	In vitro inhibition of transthyretin aggregate-induced cytotoxicity by full and peptide derived forms of the soluble receptor for advanced glycation end products (RAGE). FEBS Letters, 2006, 580, 3451-3456.	2.8	24
53	Activation of ERK1/2 MAP kinases in Familial Amyloidotic Polyneuropathy. Journal of Neurochemistry, 2006, 97, 151-161.	3.9	52
54	Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB Journal, 2006, 20, 234-239.	0.5	136

#	Article	IF	Citations
55	Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses. CNS and Neurological Disorders, 2005, 4, 587-596.	4.3	54
56	Familial Amyloidotic Polyneuropathy: Protein Aggregation in the Peripheral Nervous System. Journal of Molecular Neuroscience, 2004, 23, 035-040.	2.3	14
57	Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 2004, 381, 351-356.	3.7	88
58	X-ray Absorption Spectroscopy Reveals a Substantial Increase of Sulfur Oxidation in Transthyretin (TTR) upon Fibrillization. Journal of Biological Chemistry, 2003, 278, 11654-11660.	3.4	18
59	4 â€²â€iodoâ€4â€²â€Deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB Journal, 2003, 17, 803-809.	0.5	117
60	Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils 1 1Edited by M. Moody. Journal of Molecular Biology, 2002, 317, 683-695.	4.2	112
61	Sulphur K-edge XANES Spectroscopy of Transthyretin Amyloid Fibres. Spectroscopy, 2002, 16, 281-283.	0.8	0
62	Deposition of Transthyretin in Early Stages of Familial Amyloidotic Polyneuropathy. American Journal of Pathology, 2001, 159, 1993-2000.	3.8	303
63	Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants. Journal of Biological Chemistry, 2001, 276, 27207-27213.	3.4	274
64	Aprotinin binding to amyloid fibrils. FEBS Journal, 2000, 267, 2307-2311.	0.2	20
65	4â€²-Iodo-4â€²-Deoxydoxorubicin Disrupts the Fibrillar Structure of Transthyretin Amyloid. American Journal of Pathology, 2000, 156, 1919-1925.	3.8	55
66	Modulating Role of TTR in AÎ² Toxicity, from Health to Disease. , 0, , .		1